Immunovant Inc
NASDAQ:IMVT
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
13.31
27.54
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Immunovant Inc
NASDAQ:IMVT
|
4.6B USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
378.8B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
177.8B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
155.1B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
112.1B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.2B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
85.5B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
41.2B EUR |
Loading...
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
47.3B USD |
Loading...
|
Market Distribution
Other Profitability Ratios
Immunovant Inc
Glance View
Immunovant Inc. stands as a notable player in the biopharmaceutical industry, on a mission to develop innovative treatments for autoimmune diseases. Founded with an aim to transform the lives of patients, the company is centered around harnessing the power of monoclonal antibodies to address significant unmet medical needs. At the heart of its research and development lies a pivotal asset: a novel, fully human monoclonal antibody known as IMVT-1401. This compound targets the neonatal Fc receptor (FcRn) and has shown promise in modulating the body's immune responses, which could potentially offer relief to those suffering from debilitating autoimmune conditions. By engaging in advanced clinical trials, Immunovant aims to validate the efficacy and safety of its treatments, and bring them successfully through regulatory approvals—a process that underpins the core of its operations. Immunovant monetizes its groundbreaking research through strategic partnerships, funding initiatives, and ultimately, the commercialization of its developed therapeutics. The company’s progress is closely watched by investors and analysts who are keen on its ability to navigate the complex paths of drug development and approval. Generating revenue depends heavily on reaching key developmental milestones, gaining marketing approval, and securing licenses or collaborations with larger pharmaceutical companies—a common pathway in the biopharma sector. These ventures reflect Immunovant’s strategy to build a competitive edge through cutting-edge science and strategic alliances, thus working towards the broader goal of addressing critical health challenges and achieving financial sustainability.